You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 582 Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Eastern cooperative oncology group (ECOG) performance status subgroups in EMPOWER-Lung 1

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials Completed
582 Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Eastern cooperative oncology group (ECOG) performance status subgroups in EMPOWER-Lung 1
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Kilickap S, Sezer A, Gümüş M, et al
582 Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Eastern cooperative oncology group (ECOG) performance status subgroups in EMPOWER-Lung 1
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0582